Healthcare of Ontario Pension Plan Trust Fund Purchases 116,300 Shares of Eli Lilly and Company (NYSE:LLY)

Healthcare of Ontario Pension Plan Trust Fund grew its position in Eli Lilly and Company (NYSE:LLY) by 38.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 417,700 shares of the company’s stock after acquiring an additional 116,300 shares during the period. Eli Lilly and Company comprises about 0.8% of Healthcare of Ontario Pension Plan Trust Fund’s portfolio, making the stock its 20th largest holding. Healthcare of Ontario Pension Plan Trust Fund’s holdings in Eli Lilly and Company were worth $243,486,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Lipe & Dalton acquired a new position in shares of Eli Lilly and Company in the fourth quarter valued at $26,000. Tidemark LLC bought a new stake in shares of Eli Lilly and Company during the 4th quarter worth about $29,000. Core Wealth Advisors Inc. grew its stake in Eli Lilly and Company by 188.2% in the 4th quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after buying an additional 32 shares during the last quarter. Optiver Holding B.V. bought a new position in Eli Lilly and Company in the 3rd quarter valued at about $36,000. Finally, Frank Rimerman Advisors LLC acquired a new stake in Eli Lilly and Company during the fourth quarter worth approximately $37,000. Institutional investors own 82.53% of the company’s stock.

Insiders Place Their Bets

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 194,978 shares of the company’s stock in a transaction dated Monday, June 17th. The stock was sold at an average price of $885.91, for a total value of $172,732,959.98. Following the completion of the transaction, the insider now owns 97,583,810 shares of the company’s stock, valued at approximately $86,450,473,117.10. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, EVP Johna Norton sold 7,056 shares of Eli Lilly and Company stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $819.38, for a total transaction of $5,781,545.28. Following the transaction, the executive vice president now owns 25,428 shares in the company, valued at $20,835,194.64. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, major shareholder Lilly Endowment Inc sold 194,978 shares of the stock in a transaction on Monday, June 17th. The shares were sold at an average price of $885.91, for a total value of $172,732,959.98. Following the completion of the sale, the insider now owns 97,583,810 shares of the company’s stock, valued at $86,450,473,117.10. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 762,804 shares of company stock valued at $648,109,138. 0.13% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

LLY has been the topic of several research reports. Bank of America upped their target price on Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research report on Friday, March 1st. TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Citigroup upped their price target on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research note on Tuesday, April 2nd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $885.00 price objective on shares of Eli Lilly and Company in a research note on Monday. Finally, DZ Bank downgraded shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective for the company. in a report on Wednesday, February 21st. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus target price of $787.53.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $891.46 on Wednesday. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35. Eli Lilly and Company has a 52 week low of $434.34 and a 52 week high of $894.87. The stock has a market capitalization of $847.25 billion, a P/E ratio of 131.29, a price-to-earnings-growth ratio of 1.92 and a beta of 0.36. The stock has a fifty day moving average of $790.79 and a 200-day moving average of $723.56.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Monday, May 6th. The company reported $2.58 EPS for the quarter, topping the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The firm had revenue of $8.77 billion during the quarter, compared to the consensus estimate of $8.94 billion. During the same quarter in the previous year, the firm earned $1.62 earnings per share. The business’s quarterly revenue was up 26.0% on a year-over-year basis. On average, sell-side analysts expect that Eli Lilly and Company will post 13.76 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, June 10th. Shareholders of record on Thursday, May 16th were given a $1.30 dividend. The ex-dividend date was Wednesday, May 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.58%. Eli Lilly and Company’s dividend payout ratio is currently 76.58%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.